Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 111.07M P/E - EPS this Y 32.40% Ern Qtrly Grth -
Income -161.09M Forward P/E -1.73 EPS next Y 56.30% 50D Avg Chg 35.00%
Sales -333k PEG - EPS past 5Y - 200D Avg Chg 75.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -12.00%
Recommedations 1.30 Quick Ratio 2.21 Shares Outstanding 114.85M 52W Low Chg 284.00%
Insider Own 5.31% ROA -56.90% Shares Float 83.26M Beta 2.03
Inst Own 95.38% ROE -473.39% Shares Shorted/Prior 10.82M/9.56M Price 1.92
Gross Margin - Profit Margin - Avg. Volume 234,882 Target Price 12.80
Oper. Margin -14,194.44% Earnings Date Nov 7 Volume 1,911,233 Change 12.28%
About Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics, Inc. News
11/07/24 Applied Therapeutics Reports Third Quarter 2024 Financial Results
11/05/24 Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
10/29/24 Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know
10/29/24 Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year?
10/10/24 Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year?
09/24/24 Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
09/23/24 All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy
09/19/24 APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
09/18/24 Why Applied Therapeutics Stock Is Skyrocketing Today
09/18/24 Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug
09/18/24 Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
09/04/24 Applied Therapeutics to Participate in Upcoming Investor Conferences
08/07/24 Applied Therapeutics Reports Second Quarter 2024 Financial Results
08/06/24 Applied Therapeutics, Inc. (NASDAQ:APLT): When Will It Breakeven?
07/31/24 Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
07/01/24 Applied Therapeutics Added to Russell 3000® Index
06/29/24 Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now?
06/26/24 Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
05/10/24 Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...
05/09/24 Applied Therapeutics Reports First Quarter 2024 Financial Results
APLT Chatroom

User Image lucky9150 Posted - 7 hours ago

$APLT , even with approval, this will tank...

User Image Night_Owl_Biotech Posted - 1 day ago

The attachment documents the F2027 revenue multiple of 4 pre-commercial bios with active PDUFA dates including $APLT $KALV $HUMA & $MIST The table also notes valuation related data points around recent royalty investments by 3rd-party investors. Some believe these 3rd-party investments provide a barometer around product valuation. MIST's royalty financing was transacted before MIRT received a refusal to file letter from the FDA for its Etripamil NDA submission. As best we can tell, MIST's royalty financing commitment is still active. KALV & HUMA share prices are down 10%+ from recent third-party stock purchases within the last month. MIST & KALV trade at the lowest FY2027 revenue multiples. This is not investment advice. None of the 4 profiled have any FDA approved products & could go bankrupt if their filings are not approved. As always, we do not use automation so there may be inadvertent mistakes in the raw data $XBI

User Image Willdowdell Posted - 1 day ago

$APLT Don’t forget the voucher they’ll get upon approval… I saw where recently one sold for 125 mill..

User Image Juelz_Horn Posted - 1 day ago

$APLT $AVBP LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image RealInfo Posted - 3 days ago

$APLT PUMP AND DUMP YOU BITCH-ASS PUSSYS

User Image RealInfo Posted - 3 days ago

$APLT This isn't a STOCK it's a fuckin CARNIVAL GAME.

User Image RealInfo Posted - 3 days ago

$APLT Friggin P O S Manipulation of this P O S Stock. Hope all of u burn in Hell!

User Image nevermind889 Posted - 5 days ago

$APLT Down 18% since recent 52-week high (this past Monday). Lot of market uncertainty with Trump's pick to head HHS who is Anti Vaccine. Biotech sector definitely is suffering from it. Less than 2 weeks for FDA approval. Q1 2025 is also scheduled for EMA approval with significant milestone payment from their partner Advanz Pharma in Europe. They always take it down before big news/approval, but seems broader macro events are eroding things quickly. GLTA!

User Image FyCkD_FuNnY Posted - 6 days ago

$APLT And Blocked

User Image VaingloryInvestor Posted - 6 days ago

$APLT. Patience on this garbage if you're in. I've traded it both ways. Good runs. Hyped, manipulated and overpriced.

User Image WallStreetIsNotEasy Posted - 1 week ago

$APLT See you guys at $14-$100 cause that’s where we are heading I don’t give a flying fuk what any of you say😉

User Image RealInfo Posted - 1 week ago

$APLT I'll reiterate what I said yesterday regarding APLT and All Pharm Stocks: This downturn is all about the RFK/DJT ANGLE.

User Image TheMyth2020 Posted - 1 week ago

$APLT Welp stopped out for a 5k loss, i am deff done with this bio tech crap.

User Image Clovus33 Posted - 1 week ago

$APLT I posted the November 12th conference. I also added more shares yesterday at the $9 level.

User Image Clovus33 Posted - 1 week ago

$APLT https://event.webcasts.com/viewer/event.jsp?ei=1694533&tp_key=c6afc6cb6f

User Image MondeVest Posted - 1 week ago

$APLT A couple recent posts have wondered about what was disclosed at yesterday's presentation at the conference. See my post yesterday (Tuesday) at about 1PM EST, which included a link to the audio of the presentation. Listen to it - it's quite short. No bad news at all.

User Image DominationLeague Posted - 1 week ago

$APLT MA(50) is at 8.06. That is the next stop. Gap to fill at 6.50. MA(200) is at 5.89. Next few weeks should be interesting. Bullish long term.

User Image nevermind889 Posted - 1 week ago

$APLT Most added positions in today's filings. Some sold.

User Image nevermind889 Posted - 1 week ago

$APLT Disregard what I post on Alexandria. I thought that was the current 13G.

User Image nevermind889 Posted - 1 week ago

$APLT From today's SC 13G/A. Alexandria Real Estate Esquities sold 575,000 shares. That still leaves them with 12,859,054 shares~36.8m USD position. In addition, Venrock Healthcare Capital LLC added 2,080,232 shares bringing their total to 7,877,817 shares. Very interesting!! GLTA!

User Image Darth_Barrister Posted - 1 week ago

$APLT No. It would be same answer if it pops on positive news.

User Image nevermind889 Posted - 1 week ago

@Willdowdell @RealInfo there was some sus activity in yesterday AH, bout 770k shares dumped at 9.90 ppl are always afraid (WITH GOOD REASON) that the biotech play won't pan out, aka, approval won't happen. that's the risk we all take buying the stock $aplt we're at 9$ and the stock was $2 a year ago. profit taking will always be a no brainer

User Image nevermind889 Posted - 1 week ago

@RealInfo u win some, u lose some, i added to my position though $aplt

User Image nevermind889 Posted - 1 week ago

$APLT Did the stock hit SSR today?? Was really close....

User Image WallStreetIsNotEasy Posted - 1 week ago

$APLT we will wake up to glorious news and it will be trading in the teens one fine morning 👌

User Image RealInfo Posted - 1 week ago

$APLT Anyone bragging right now about BUYING THE DIP? I DIDN'T THINK SO! (A) SOMEONE HAS KNOWLEDGE ABOUT THIS STOCK THAT THE REST OF US MERE MORTALS DONT HAVE. (B)Or whatever was said at that Conference yesterday has tanked the stock. And it could be both (A) and (B)

User Image Alphasearch Posted - 1 week ago

$APLT Did anybody listen to yesterday's health conference that they presented? Was it not good? I bought more yesterday

User Image RealInfo Posted - 1 week ago

$APLT Here is an interesting observation: APLT is moving downward in lock-step with VKTX. Both were the hot ticket for drug development and both are bombing together. Is this TRUMP/RFK related?

User Image flyinghollaender Posted - 1 week ago

$APLT bought a bunch. With upcoming caralyst this will easily reach >11$

User Image WallStreetIsNotEasy Posted - 1 week ago

$APLT looks like a coordinated attack on most biotech stocks They are white collar criminals whose #1 goal is to shake retail They want YOUR shares cheaper than you paid

Analyst Ratings
Citigroup Buy Sep 19, 24
Leerink Partners Outperform Sep 19, 24
Citigroup Buy Aug 27, 24
William Blair Outperform Jul 31, 24
RBC Capital Outperform Jul 17, 24
RBC Capital Outperform Apr 11, 24
RBC Capital Outperform Mar 26, 24
UBS Buy Mar 15, 24
UBS Buy Mar 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kanter Stacy J. Director Director Dec 01 Buy 2.1789 30,000 65,367 63,000 12/05/23
Shendelman Shoshana President and CEO President and CEO Nov 30 Sell 1.97 3,968 7,817 2,596,387 12/01/23
Perfetti Riccardo Chief Medical Office.. Chief Medical Officer Nov 30 Sell 1.97 1,583 3,119 692,341 12/01/23
Hansard Adam Chief Commercial Off.. Chief Commercial Officer Nov 30 Sell 1.97 965 1,901 381,790 12/01/23
ALEXANDRIA REAL ESTATE EQUITIE... 10% Owner 10% Owner Nov 02 Sell 2.32 247,258 573,639 5,580,077 11/06/23
Shendelman Shoshana President and CEO President and CEO Sep 27 Sell 2.70 115,632 312,206 2,600,355 09/29/23
Perfetti Riccardo Chief Medical Office.. Chief Medical Officer Sep 27 Sell 2.70 10,932 29,516 693,924 09/29/23
Hansard Adam Chief Commercial Off.. Chief Commercial Officer Sep 27 Sell 2.70 9,720 26,244 382,755 09/29/23
MARCUS JOEL S Director Director Sep 15 Option 1.05 12,375 12,994 453,414 09/19/23
Hansard Adam Chief Commercial Off.. Chief Commercial Officer Jan 11 Sell 0.91 4,495 4,090 92,475 01/13/23
Shendelman Shoshana President and CEO President and CEO Oct 12 Buy 0.5227 38,153 19,943 644,239 10/12/22
MARCUS JOEL S Director Director Apr 14 Option 7.35 48,982 360,018 67,435 09/16/22
MARCUS JOEL S Director Director Sep 14 Option 1.05 38,244 40,156 421,039 09/16/22
ALEXANDRIA REAL ESTATE EQUITIE... 10% Owner 10% Owner Jun 27 Buy 1 3,500,000 3,500,000 4,555,077 06/29/22
Mahadevan Chids See Remarks See Remarks May 16 Sell 1.65 905 1,493 9,800 05/18/22
Perfetti Riccardo Chief Medical Office.. Chief Medical Officer Mar 21 Buy 1.93 64,509 124,502 160,909 03/23/22
Shendelman Shoshana President and CEO President and CEO Sep 14 Buy 14.59 10,001 145,915 364,286 09/14/21